Endurance Wealth Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-50
| Closed | – | – | 611 |
|
|
2019
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 561 |
|
|
2019
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 556 |
|
|
2019
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 497 |
|
|
2019
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 500 |
|
|
2018
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 511 |
|
|
2018
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 510 |
|
|
2018
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 538 |
|
|
2018
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 551 |
|
|
2017
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 529 |
|
|
2017
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 536 |
|
|
2017
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 540 |
|
|
2017
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 536 |
|
|
2016
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 512 |
|
|
2016
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 527 |
|
|
2016
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 526 |
|
|
2016
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 546 |
|
|
2015
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 549 |
|
|
2015
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 567 |
|
|
2015
Q2 | $0 | Buy |
+50
| New | +$35 | ﹤0.01% | 546 |
|
Endurance Wealth Management's GCVRZ Position: Q1 2020 in Review
Endurance Wealth Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 50 shares.
Endurance Wealth Management first reported a position in GCVRZ in Q2 2015 and held it in 19 quarters. The position peaked at $0 in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Endurance Wealth Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Endurance Wealth Management sold 50 Sanofi Contingent Value Rights shares in Q1 2020.
- Endurance Wealth Management first reported a position in Sanofi Contingent Value Rights in Q2 2015 and held it in 19 quarters.
- Endurance Wealth Management's Sanofi Contingent Value Rights position peaked at $0 in Q4 2019.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Endurance Wealth Management's 13F filing for Q1 2020, filed 17 Apr 2020.